Zacks Research Upgrades Amneal Pharmaceuticals (NASDAQ:AMRX) to “Hold”

Amneal Pharmaceuticals (NASDAQ:AMRX) was upgraded by Zacks Research from a “strong sell” rating to a “hold” rating in a report issued on Monday, Zacks reports.

A number of other brokerages also recently issued reports on AMRX. JPMorgan Chase & Co. lifted their price target on Amneal Pharmaceuticals from $22.00 to $24.00 and gave the company an “overweight” rating in a report on Thursday, October 22nd. UBS Group reissued a “buy” rating on shares of Amneal Pharmaceuticals in a research report on Thursday, October 1st. Weiss Ratings upgraded Amneal Pharmaceuticals from a “buy (b-)” rating to a “buy (b)” rating in a research note on Thursday, October 8th. Leerink Partners initiated coverage on Amneal Pharmaceuticals in a research report on Wednesday, September 9th. They set an “outperform” rating and a $23.00 price objective on the stock. Finally, The Goldman Sachs Group reaffirmed a “buy” rating and set a $21.00 price objective on shares of Amneal Pharmaceuticals in a research report on Friday, July 31st. Nine investment analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company’s stock. Based on data from MarketBeat, Amneal Pharmaceuticals has an average rating of “Moderate Buy” and a consensus price target of $21.25.

Amneal Pharmaceuticals Stock Performance

NASDAQ:AMRX opened at $21.44 on Monday. The firm has a 50-day simple moving average of $18.93 and a 200-day simple moving average of $15.62. Amneal Pharmaceuticals has a one year low of $9.99 and a one year high of $21.46.

Amneal Pharmaceuticals (NASDAQ:AMRX) last released its quarterly earnings data on Thursday, July 30th. The company reported $0.30 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.24 by $0.06. The business had revenue of $796.20 million for the quarter. Amneal Pharmaceuticals has set its FY 2026 guidance at 0.960-1.060 EPS. On average, research analysts forecast that Amneal Pharmaceuticals will post 0.95 earnings per share for the current year.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, EVP Nikita Shah sold 146,403 shares of the company’s stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.51, for a total value of $2,563,516.53. Following the sale, the executive vice president owned 253,390 shares in the company, valued at $4,436,858.90. This represents a 36.62% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Jason B. Daly sold 210,000 shares of the stock in a transaction that occurred on Wednesday, August 12th. The stock was sold at an average price of $17.40, for a total transaction of $3,654,000.00. Following the completion of the transaction, the executive vice president owned 35,171 shares in the company, valued at approximately $611,975.40. This trade represents a 85.65% decrease in their position. The SEC filing for this sale provides additional information. In the last 90 days, insiders have sold 413,016 shares of company stock worth $7,216,567. 17.30% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Amneal Pharmaceuticals

A number of institutional investors have recently bought and sold shares of the business. Park Avenue Securities LLC boosted its holdings in shares of Amneal Pharmaceuticals by 28.1% in the 3rd quarter. Park Avenue Securities LLC now owns 15,668 shares of the company’s stock valued at $316,000 after acquiring an additional 3,436 shares during the last quarter. Gibbs Wealth Management acquired a new stake in shares of Amneal Pharmaceuticals in the third quarter worth $613,000. Sterling Capital Management LLC increased its stake in shares of Amneal Pharmaceuticals by 30.3% in the third quarter. Sterling Capital Management LLC now owns 3,549 shares of the company’s stock worth $71,000 after acquiring an additional 825 shares during the period. Yousif Capital Management LLC raised its holdings in shares of Amneal Pharmaceuticals by 2.9% during the third quarter. Yousif Capital Management LLC now owns 42,839 shares of the company’s stock worth $863,000 after purchasing an additional 1,197 shares during the last quarter. Finally, Signature Wealth Management Partners LLC purchased a new position in shares of Amneal Pharmaceuticals during the third quarter worth $4,681,000. 31.82% of the stock is owned by hedge funds and other institutional investors.

Amneal Pharmaceuticals Company Profile

Amneal Pharmaceuticals, Inc is a specialty pharmaceutical company that develops, manufactures and commercializes a broad portfolio of generic and specialty medicines. Its products include oral, injectable and inhaled medications, as well as complex dosage forms and other products designed to address areas where manufacturing or formulation requirements can be more challenging.

The company’s generics business offers medicines across a range of therapeutic categories, including central nervous system, cardiovascular, gastrointestinal, anti-infective and other treatments.